Eupraxia Pharmaceuticals (EPRX) Price & Analysis

Compare

40 Followers

EPRX Stock Chart & Stats

C$8.40

C$0.00(0.00%)

At close: Jan 08 4:00 PM EST

C$8.40

C$0.00(0.00%)

Day’s Range― - ―

52-Week RangeC$3.07 - C$9.75

Previous CloseN/A

Volume2.50K

Average Volume (3M)52.14K

Market Cap

C$429.74M

Enterprise ValueC$295.74M

Total Cash (Recent Filing)C$27.45M

Total Debt (Recent Filing)C$52.77K

Price to Earnings (P/E)―

Beta0.63

Next Earnings

Nov 05, 2025

EPS Estimate

-0.25

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.33

Shares Outstanding50,596,930

10 Day Avg. Volume39,219

30 Day Avg. Volume52,143

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$15.56

Price Target Upside85.24% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Commercial PotentialThe durable twelve-month efficacy and validation of once-yearly dosing further expands the commercial potential of EP-104GI in a U.S. EoE market exceeding one million patients.

Competitive PositioningThe 12-month durability data strengthen EP-104GI’s competitive positioning in a growing EoE market that could exceed one million U.S. patients.

Safety And EfficacyEP-104GI demonstrated a favorable safety profile, with plasma fluticasone levels remaining low and consistent, and no serious adverse events reported.

Bears Say

Financial PerformanceFor Q2 2025, Eupraxia reported a net loss of $8.7M versus $6.1M in Q2 2024, driven by higher R&D and G&A expenses.

Eupraxia Pharmaceuticals News

Closing Bell Movers: Progress Software up 4%, Jefferies slips 1% on earnings

In the opening hour of evening session, U.S. equity futures are modestly lower, with S&P 500, Dow Industrials,...

16d ago

IDT

JEF

Eupraxia announces ‘positive’ data from highest-dose cohort in RESOLVE trial

Eupraxia Pharmaceuticals (EPRX) provided an operational update on the development of EP-104GI, including reporting data from patients in...

16d ago

EPRX

Eupraxia Pharmaceuticals 12.727M share Spot Secondary priced at $5.50

Cantor Fitzgerald and LifeSci Capital acted as joint book running managers for the offering. Published first on TheFly...

23d ago

EPRX

Closing Bell Movers: ACM Research up 5% after joining S&P SmallCap 600

In the opening hour of the evening session, U.S. equity futures are down modestly as the momentum propelling...

23d ago

FLY

JNJ

Eupraxia Pharmaceuticals announces common shares offering, no amount given

Eupraxia Pharmaceuticals (EPRX) has filed a preliminary prospectus supplement to its short form base shelf prospectus dated February...

23d ago

EPRX

Promising Phase 2b Advancement of EP-104GI Boosts Buy Rating Amid Positive RESOLVE Trial Results

H.C. Wainwright analyst Brandon Folkes has reiterated their bullish stance on EPRX stock, giving a Buy rating yesterday....

14d ago

EPRX

Eupraxia Pharmaceuticals Reports Positive Results in EoE Trial and Plans Expansion

An update from Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) is now available. On September 29, 2025, Eupraxia Pharmaceuticals announced...

14d ago

EPRX

Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering

Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has provided an update. On September 24, 2025, Eupraxia Pharmaceuticals Inc. announced the...

16d ago

EPRX

Eupraxia Pharmaceuticals Secures $80.5 Million in Public Offering

Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has provided an announcement. On September 24, 2025, Eupraxia Pharmaceuticals announced the successful...

21d ago

EPRX

Eupraxia Pharmaceuticals Announces Major Share Offering to Boost Capital

Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has provided an announcement. On September 22, 2025, Eupraxia Pharmaceuticals Inc. announced an...

22d ago

EPRX

Eupraxia Pharmaceuticals Prices $70 Million Public Offering

Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has shared an announcement. On September 22, 2025, Eupraxia Pharmaceuticals announced the pricing...

22d ago

EPRX

Eupraxia Pharmaceuticals Announces Public Offering to Fund Pipeline Expansion

An update from Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) is now available. On September 22, 2025, Eupraxia Pharmaceuticals announced...

23d ago

EPRX

Eupraxia Pharmaceuticals Appoints New CFO Amid Leadership Transition

An update from Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) is now available. On February 18, 2025, Eupraxia Pharmaceuticals announced...

26d ago

EPRX

Eupraxia Pharmaceuticals’ EP-104GI: A Promising Annual Treatment for Eosinophilic Esophagitis with Significant Market Potential

Analyst Brandon Folkes of H.C. Wainwright reiterated a Buy rating on Eupraxia Pharmaceuticals, retaining the price target of...

1M ago

EPRX

EPRX FAQ

What was Eupraxia Pharmaceuticals’s price range in the past 12 months?

Eupraxia Pharmaceuticals lowest stock price was C$3.07 and its highest was C$9.75 in the past 12 months.

What is Eupraxia Pharmaceuticals’s market cap?

Eupraxia Pharmaceuticals’s market cap is C$429.74M.

When is Eupraxia Pharmaceuticals’s upcoming earnings report date?

Eupraxia Pharmaceuticals’s upcoming earnings report date is Nov 05, 2025 which is in 21 days.

How were Eupraxia Pharmaceuticals’s earnings last quarter?

Eupraxia Pharmaceuticals released its earnings results on Aug 12, 2025. The company reported -C$0.333 earnings per share for the quarter, missing the consensus estimate of -C$0.256 by -C$0.077.

Is Eupraxia Pharmaceuticals overvalued?

According to Wall Street analysts Eupraxia Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Eupraxia Pharmaceuticals pay dividends?

Eupraxia Pharmaceuticals does not currently pay dividends.

What is Eupraxia Pharmaceuticals’s EPS estimate?

Eupraxia Pharmaceuticals’s EPS estimate is -0.25.

How many shares outstanding does Eupraxia Pharmaceuticals have?

Eupraxia Pharmaceuticals has 50,596,930 shares outstanding.

What happened to Eupraxia Pharmaceuticals’s price movement after its last earnings report?

Eupraxia Pharmaceuticals reported an EPS of -C$0.333 in its last earnings report, missing expectations of -C$0.256. Following the earnings report the stock price went up 0.537%.

Which hedge fund is a major shareholder of Eupraxia Pharmaceuticals?

Currently, no hedge funds are holding shares in TSE:EPRX

Eupraxia Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-158.24%

Trailing 12-Months

Asset Growth

-5.79%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals (EPRX) is a clinical-stage biotechnology company focused on developing innovative drug products for the treatment of chronic diseases. The company's primary focus is on creating long-acting formulations that aim to provide sustained therapeutic effects, particularly in areas with significant unmet medical needs such as osteoarthritis and other pain-related conditions. Eupraxia's lead product candidate is EP-104IAR, a proprietary sustained-release formulation intended to alleviate pain and improve joint function in patients with osteoarthritis.

Eupraxia Pharmaceuticals (EPRX) Earnings & Revenues

Historic Earnings Reports

EPRX Stock 12 Month Forecast

Average Price Target

C$15.56

▲(85.24% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"C$3","20":"C$20","7.25":"C$7.25","11.5":"C$11.5","15.75":"C$15.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19.65339824,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$19.65</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$15.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,7.25,11.5,15.75,20],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.5,9.35795371076923,10.215907421538462,11.073861132307693,11.931814843076923,12.789768553846155,13.647722264615386,14.505675975384616,15.363629686153846,16.22158339692308,17.07953710769231,17.93749081846154,18.79544452923077,{"y":19.65339824,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.5,9.043076923076923,9.586153846153847,10.12923076923077,10.672307692307692,11.215384615384615,11.758461538461539,12.301538461538462,12.844615384615384,13.387692307692308,13.930769230769231,14.473846153846154,15.016923076923078,{"y":15.56,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.5,8.538461538461538,8.576923076923077,8.615384615384615,8.653846153846153,8.692307692307692,8.73076923076923,8.76923076923077,8.807692307692308,8.846153846153847,8.884615384615385,8.923076923076923,8.961538461538462,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.74,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.27,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.51,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.45,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.7,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.7,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.38,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >